Modern POI diagnosis, real fertility choices, honest limits
Stem cell therapy for premature ovarian insufficiency in Istanbul, Turkey
Our Istanbul reproductive health team confirms your diagnosis, protects your hormone and fertility options, and explains early cell research honestly.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Direct answer
What the current evidence says
We use the preferred term premature ovarian insufficiency because ovarian activity can fluctuate — many patients search for premature ovarian failure. We're candid that stem cell therapy has not been shown to regenerate eggs, restore reserve, or produce pregnancy. Our physicians focus on confirming your diagnosis, protecting your bone and cardiovascular health with appropriate hormone therapy, and discussing your real fertility options alongside any early-stage research context. Request your free medical evaluation for a caring, honest consultation.
Evidence position
What is known, what is investigational, and what is not demonstrated
Honest diagnosis and fertility counseling first
Premature ovarian insufficiency is the preferred term because ovarian activity can fluctuate; premature ovarian failure remains a common search synonym.
Intraovarian is invasive
We diagnose using menstrual history and repeat hormone assessment, and explain AMH's real limitations rather than overselling it.
Biomarkers are not live birth
Results vary between patients and stem cell therapy is not a guaranteed cure — hormone therapy protects your health but is not fertility treatment.
Evidence ledger
Read the actual study, including the result that did not change
Each row keeps product identity, route, endpoint, and limitation together so one trial cannot become a generic treatment claim.
01 Autologous menstrual blood-derived MSC pilot in POI
Open source- Product
- Autologous menstrual blood-derived mesenchymal stromal cells
- Route
- Intraovarian administration
- Design
- Small early-phase uncontrolled study of 15 participants
- Finding
- The study explored feasibility and ovarian-function markers.
- Limitation
- The small uncontrolled design did not establish fertility benefit, and AMH did not show a significant improvement.
Clinical map
Start with the diagnosis, stage, and treatment context
We never promise new follicles, spontaneous pregnancy, or live birth from a cell product.
Established care comes first
- Hormone health: We use physiologic hormone replacement when appropriate until the usual age of menopause, with individualized review.
- Fertility counseling: We discuss intermittent ovarian activity, donor-oocyte IVF, and other pathways honestly, without false certainty.
- Long-term support: We assess bone density, cardiovascular risk, and mental health as part of your ongoing care.
- 01
Confirm the diagnosis
We exclude pregnancy and evaluate menstrual disturbance with repeat FSH and estradiol in the correct clinical context.
- 02
Find a cause when possible
Genetic testing, autoimmune review, and treatment history may reveal a cause worth addressing.
- 03
Separate health and fertility goals
Hormone health, oocyte options, and pregnancy planning are distinct decisions we walk through with you.
Product and route
A mechanism is not a clinical outcome
- 01
Intraovarian is invasive
Needle placement carries bleeding, infection, and anesthesia risk, and requires a reproductive-medicine setting we take seriously.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
- 02
Biomarkers are not live birth
We won't let a change in FSH, AMH, or follicle count stand in for oocyte quality, pregnancy, or live birth.
BoundaryEvidence applies only to the studied product, population, dose, route, comparator, and endpoint.
Outcomes before travel
Decide what meaningful change would look like
A baseline and a time point matter more than an isolated testimonial. These measures should be chosen before any intervention.
- 01
Menstrual and ovulation pattern
- 02
FSH, estradiol, and AMH with known limitations
- 03
Antral follicle count
- 04
Oocyte retrieval, embryo, pregnancy, and live birth outcomes
- 05
Bone, symptoms, safety, and psychological wellbeing
Specialist review
What a complete Istanbul review needs
Our Istanbul reproductive health team confirms your diagnosis, protects your hormone and fertility options, and explains early cell research honestly.
Records and baseline
- Age, menstrual timeline, pregnancy testing, repeat FSH and estradiol
- AMH and antral follicle count interpreted cautiously
- Karyotype, FMR1, autoimmune, thyroid, and family history
- Bone density, cardiovascular risk, and fertility goals
- The exact product, technique, and reproductive outcomes we discuss with you
Safety and planning checks
- We never postpone time-sensitive fertility counseling for an unproven regenerative procedure.
- Your Istanbul plan includes reproductive endocrinology, procedural safety, and follow-up with your home clinician.
- We never combine menstruation, hormone changes, pregnancy, and live birth into one invented success rate.
Transparent planning
Build the medical plan before the package
A quote should follow record review, product disclosure, route rationale, and a written follow-up plan. This page does not invent a universal price.
- We never postpone time-sensitive fertility counseling for an unproven regenerative procedure.
- Your Istanbul plan includes reproductive endocrinology, procedural safety, and follow-up with your home clinician.
- We never combine menstruation, hormone changes, pregnancy, and live birth into one invented success rate.
Questions the plan must answer
- 01
Intraovarian is invasive: Needle placement carries bleeding, infection, and anesthesia risk, and requires a reproductive-medicine setting we take seriously.
- 02
Biomarkers are not live birth: We won't let a change in FSH, AMH, or follicle count stand in for oocyte quality, pregnancy, or live birth.
Primary reading
Guidelines, trials, and regulatory context
FAQ
Questions patients ask before an Istanbul review
Request Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.